Effect of statin therapy on serum trace element status in dyslipidaemic subjects

Ghayour‐Mobarhan, Majid; Lamb, David; Taylor, Andrew; Vaidya, Nandita; Livingstone, Callum; Wang, Yichen; Ferns, Gordon A.

doi:10.1016/j.jtemb.2005.06.003

Cited by 34 publications

(27 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…That study sample size, however, was rather low (nine patients) and the same effect was not observed in simvastatin-using patients. 29 In summary, it seems unlikely that coronary artery disease, in itself, was causative in this study, because all patients in all three study groups had CAD and there little difference in group characteristics (except for the use of ASA, beta blockers and ARB). According to our regression analysis, statin use seems to be an independent determinant of Cp elevation.…”

Section: Discussionmentioning

confidence: 68%

Effects of statin use on total oxidant and antoxidant capacity and ceruloplasmin activity

Büyükhatipoğlu

Sezen²,

Yıldız³

et al. 2010

CIM

View full text Add to dashboard Cite

Clin Invest Med 2010; 33 (5): E313-E320. AbstractPurpose: Oxidative damage plays an important role in atherosclerosis development. Statin drugs have anti-oxidant properties, but the clinical value of their antioxidant properties remains unclear. In this study, our aims were: (1) to assess the anti-oxidant effects of statins in patients with coronary artery disease (CAD) using a newly developed valid measure of total oxidant and anti-oxidant capacity; and (2) to identify whether statins influence ceruloplamin levels. Methods: Within a cross-sectional study, 67 dyslipidemic CAD patients on atorvastatin for at least three months were compared with 69 age-and gender-matched CAD patients not using atorvastatin. All patients were either newlydiagnosed with or already had established CAD. Patients and controls were selected from among patients who had undergone coronary angiography for a variety of reasons. Immediately prior to angiography, plasma total oxidant and antioxidant capacity and ceruloplasmin (Cp) levels were measured by means of a relatively new and highly-reliable method. Results: Total oxidant capacity levels were significantly lower and total antioxidant capacity significantly higher in those on atorvastatin; serum seruloplasmin levels also were significanly increased in the atorvastatin groups (all p < 0.05). On multivariate analysis, atorvastatin use was a significant determinant of Cp increase, independent of any antioxidant effect. Conclusions: This study clearly demonstrates increased anti-oxidant capacity and decreased oxidative stress with statin use. Atorvastatin use may also increase Cp levels although this effect appears to be independent of its antioxidant effects.Free radicals and oxidants are produced in metabolic and physiological processes, and their effects are controlled by exogenous and endogenous antioxidants. If the quantity of free radicals exceeds the capacity of anti-oxidant defense mechanisms, oxidative stress occurs. 1,2 Oxidative stress alters normal endothelial functions, inducing proinflammatory, prothrombotic, proliferative and vasoconstrictor mechanisms that support atherogenic processes. 2,3 A number of reports in the literature implicate oxidative stress and/or inadequate antioxidant defences in the pathogenesis of, or as a risk factor for, cardiovascular disease. 4,5 Ischemic heart disease is an ideal example of a clinical situation in which there is an increased production of oxygen free radicals. 6 Oxi-ORIGINAL RESEARCH

show abstract

Section: Discussionmentioning

confidence: 68%

Effects of statin use on total oxidant and antoxidant capacity and ceruloplasmin activity

Büyükhatipoğlu

Sezen²,

Yıldız³

et al. 2010

CIM

View full text Add to dashboard Cite

show abstract

“…As a secondary analysis, the small number of dyslipidemic participants might contribute to the lack of power of the analysis as the larger decrease in plasma selenium in the statin group did not reach the statistical significance. Previous reports conducted on a short period and on a limited number of patients did not show any effect of statins on plasma selenium variations [38,39]. It can also be hypothesized that the response of plasma selenium to lipid lowering drugs, observed on cross-sectional analysis, reach a plateau and then is up-regulated by the changes in HDL-and LDL-cholesterol concentrations as suggested by the multiple linear regression models.…”

Section: Discussionmentioning

confidence: 85%

Fibrates but not statins increase plasma selenium in dyslipidemic aged patients – The EVA study

Arnaud

Akbaraly

Hininger‐Favier

et al. 2009

Journal of Trace Elements in Medicine and Biology

View full text Add to dashboard Cite

“…Oranje et al [26] observed that atorvastatin increases the resistance to LDL-oxidation in type-2 diabetic patients. A significant reduction in mean serum Zinc (Zn), Copper (Cu), Ceruloplasmin and C-Reactive protein was recently reported after a 4-month treatment with statins in 20 dyslipidemic patients, previously never treated with a lipid-lowering drug [27]. No significant effects were then observed in serum Se and gluthatione-peroxidase activity.…”

Section: Discussionmentioning

confidence: 99%

Chronic treatment with statins increases the availability of selenium in the antioxidant defence systems of hemodialysis patients

Taccone-Gallucci

Noce

Bertucci

et al. 2010

Journal of Trace Elements in Medicine and Biology

View full text Add to dashboard Cite

a b s t r a c tProject: Oxidative stress (OS) is enhanced in hemodialysis (HD) patients. Lipid peroxidation and oxidative damage to glycids, proteins and nucleic acids are the main consequences of OS and are associated with increased cardiovascular risk. Vitamin E and glutathione peroxidase (GSH-Px) represent the main antioxidant systems in human cells. Selenium (Se), bound to the active sites of GSH-Pxs, plays a critical role in this antioxidant defence system. Statins are widely used and extensively investigated in the prevention of cardiovascular disease, notably in high-risk subjects. Several studies show antioxidant effects of statins not related to their lipid-lowering action. Our study aimed to compare serum Se concentration in ESRD patients on maintenance HD and in homogeneous healthy subjects and to investigate whether chronic treatment with statins may interfere with serum Se concentration in HD patients. Procedure: A total of 103 HD patients and 69 healthy subjects were enrolled; HD patients were divided into patients who were not treated with statins (group A) and patients who assumed statins since 6 months at least (group B). Serum Se was determined by atomic absorption spectrometry. Results: Serum Se was significantly lower in HD patients of group A compared with healthy subjects (81.65719.66 Vs. 96.47715.62 mcg/L, po0.0040). However, in HD patients who assumed statins serum, Se was significantly higher than in HD patients who did not (111.83718.82 vs. 81.65719.66 mcg/L, po0.0001). Conclusions: Our results suggest that in HD patients chronic treatment with statins is related to higherserum Se concentration.

show abstract

Effect of statin therapy on serum trace element status in dyslipidaemic subjects

Cited by 34 publications

References 28 publications

Effects of statin use on total oxidant and antoxidant capacity and ceruloplasmin activity

Effects of statin use on total oxidant and antoxidant capacity and ceruloplasmin activity

Fibrates but not statins increase plasma selenium in dyslipidemic aged patients – The EVA study

Chronic treatment with statins increases the availability of selenium in the antioxidant defence systems of hemodialysis patients

Contact Info

Product

Resources

About